ストックスクリーナーアプリを入手
7.67
0.92%
0.07
プレマーケット:
7.67
Exagen Inc (XGN) 最新ニュース
Exagen (NASDAQ: XGN) grants director options at $4.31 strike - Stock Titan
Exagen (NASDAQ: XGN) grants Paul Kim 37,500 options at $4.31 - Stock Titan
Exagen Q2 2026 slides: record revenue, stock surges 36% By Investing.com - Investing.com Nigeria
Flputnam Investment Management Co. Takes $1.34 Million Position in Exagen Inc. $XGN - MarketBeat
GSA Capital Partners LLP Makes New Investment in Exagen Inc. $XGN - MarketBeat
XGN Q2 2026 Earnings: Narrower-Than-Expected Loss Lifts SentimentEarnings Acceleration Picks - vinanet.vn
Exagen Stock Price Forecast. Should You Buy XGN? - StockInvest.us
XGN Q2 2026 Earnings: Narrower -$0.13 Loss Beats Estimates; Shares Slip 2.66%Retail Earnings Report - Vinanet
Exagen (XGN) Advances 1.96% to $6.77, Holding Above Key SupportTime Weighted Price - vinanet.vn
Exagen at Canaccord Genuity growth conference: turnaround gains pace - Investing.com
Metagenomi Therapeutics: Q2 Earnings Snapshot - AOL.com
Exagen Inc. (NASDAQ:XGN) Analysts Are Pretty Bullish On The Stock After Recent Results - webull.com
Agenus: Q2 Earnings Snapshot - aol.com
Exagen Inc. (XGN) Climbs 4.25% to $6.87, Holding Above Key SupportTPO Profile - dars.gov.et
Exagen (XGN) Q2 2026 Earnings: Narrower Loss Beats Estimates, Shares Rise 4.25%Negative Surprise Momentum - vinanet.vn
Exzeo: Q2 Earnings Snapshot - AOL.com
Xenon Pharmaceuticals: Q2 Earnings Snapshot - AOL.com
Exagen Q2 2026 Earnings: Record Revenue and Reduced EBITDA Loss - sekbernews.id
Exagen (XGN) Stock Gets Fair Value Boost As Analysts Weigh Growth And Execution - Yahoo Finance
XGN Maintains Buy Rating -- Price Target Raised to $10.00 by TD Cowen - GuruFocus
XGN Reiterates by B. Riley Securities -- Price Target Raised to $12 - GuruFocus
Exagen Inc. 2026 Q2ResultsEarnings Call Presentation (NASDAQ:XGN) 2026-08-05 - Seeking Alpha
XGN Maintained by BTIG -- Price Target Raised to $9.00 - GuruFocus
Insiders At Exagen Sold US$680k Of Stock Potentially Indicating Weakness - Moomoo
B. Riley Adjusts Price Target on Exagen to $12 From $8, Maintains Buy Rating - marketscreener.com
BTIG Research Forecasts Strong Price Appreciation for Exagen (NASDAQ:XGN) Stock - MarketBeat
Exagen Inc (XGN) (Q2 2026) Earnings Call Highlights: Record Reve - GuruFocus
Exagen: The Path To Profitability Just Became More Credible (NASDAQ:XGN) - Seeking Alpha
Exagen revenue reaches record level in Q2 2026 as test volume and ASP climb, lifts full year outlook - Traders Union
Exagen Inc. Stock 12‑Month Price Target Raised to $8.71, Implies 86% Upside - TradingView
Exagen Inc. Q2 2026 Earnings Call Summary - Yahoo Finance
Exagen Inc (XGN) (Q2 2026) Earnings Call Highlights: Record Revenue and Path to Profitability - Yahoo Finance
Exagen Q2 Earnings Call Highlights - Yahoo Finance
Earnings call transcript: Exagen tops Q2 2026 estimates, shares jump 20% - Investing.com Nigeria
Is Exagen Inc (XGN) Worth the Price After Q2 Earnings? Revenue H - GuruFocus
Exagen Reports Record Second-Quarter 2026 Revenue and Raises Full-Year Guidance - Yahoo Finance
Exagen Q2 2026 slides: record revenue, stock surges 30% on results - Investing.com
XGN: Record revenue, improved margins, and raised guidance highlight strong execution and growth - TradingView
Exagen Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
Exagen Q2 2026 slides: record revenue, stock surges 36% - Investing.com
Exagen (NASDAQ:XGN) Announces Quarterly Earnings Results - MarketBeat
Exagen Inc. reports results for the quarter ended June 30Earnings Summary - TradingView
Exagen (NASDAQ:XGN) Beats Q2 Estimates and Raises Full-Year Guidance - ChartMill
EXAGEN INC. Q2 2026: Revenue $19.94M, EPS $(0.13) — 10-Q Summary - TradingView
Exagen Inc. (XGN) Reports Q2 Loss, Beats Revenue Estimates - Yahoo Finance
XGN: Q2 2026 revenue rose 15.9% year-over-year, with improved margins and reduced net loss - TradingView
Exagen Inc. (NASDAQ: XGN) lifts Q2 2026 revenue to $19.9M - Stock Titan
Q2 2026 Exagen Inc Earnings Call Transcript - GuruFocus
Exagen Reports Record Second-Quarter Revenue and Narrows Losses, Raises Full-Year 2026 Guidance - Moomoo
Exagen Inc. Reports Second Quarter 2026 Financial Results - The Manila Times
Exagen reports Q2 2026 revenue $19.9M, narrows adjusted EBITDA loss to $0.1M - tradingview.com
Exagen reports record Q2 revenue of $19.9 million - Quiver Quantitative
XGN: Record revenue and improved margins drive higher guidance and reduced losses - TradingView
BRIEF-Exagen Inc. Q2 Revenue USD 19.941 Million Vs. IBES Estimate USD 17.8 Million - TradingView
Exagen Inc. Increases Earnings Guidance for the Full Year 2026 - marketscreener.com
XGN Q1 2026 Earnings: Narrower-Than-Expected Loss Could Not Offset Missing Revenue ClarityAdjusted Earnings Analysis - vinanet.vn
XGN Q1 2026 Earnings: Narrower-than-Expected Loss Buys Time, but Shares Slip 3%Earnings Expansion Phase - vinanet.vn
Escalade: Q2 Earnings Snapshot - AOL.com
AxoGen: Q2 Earnings Snapshot - aol.com
Exagen Inc. to Participate in Upcoming Investor Conference - The Manila Times
Exagen Inc (XGN) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Exagen Inc (XGN) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
XGN|Exagen Inc|Price:4.530|Chg%:-0.140 - TradingKey
Exagen Inc (XGN) Institutional Confidence - TradingKey
Exagen Inc (XGN) Balance Sheet - TradingKey
Exagen Inc. Revenue Breakdown – NASDAQ:XGN - TradingView
XGN Q1 2026 Earnings: Narrower-Than-Expected Loss Drives EPS Beat, Stock DeclinesRevenue Per Share - po-news-eg.net
Exagen Inc (XGN) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Exagen Inc (XGN) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Exagen Inc (XGN) Income Statement - TradingKey
XGN|Exagen Inc|Price:4.390|Chg%:-0.290 - TradingKey
0.58%
0.81%
大文字化:
|
ボリューム (24 時間):